Key Developments, Acquisitions, and Collaborations are Expected to Drive the Global mRNA Vaccine Market

Published: Mar 2022

The global mRNA vaccine market is anticipated to grow at a 16% CAGR during the forecast period (2022-2028). Key companies operating in the industry are highly inclined toward the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in September 2020, collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation was taken place to accelerate the manufacturing and delivery of up to an additional 100 million doses of future vaccines for low and middle-income countries as a part of Gavi COVAX  AMC, a mechanism within the COVAX facility. This collaboration provided upfront capital to SII to help increase the manufacturing capacity. The main purpose of this collaboration was to gain regulatory approval, to distribute the doses to low –and middle-income countries as a part of the GAVI COVAX AMC mechanism in the first half of 2021. Moreover, in August 2021, Sanofi acquired Translate Bio for $38 per share in cash, which represents a total equity value of approximately $3.2 billion. The main purpose of this acquisition was to accelerate the application of messenger RNA to develop therapeutics and vaccines to enable a better position in the market and to expand its reach to more people in a rapid way. 

Browse the full report description of Global mRNA Vaccine Market Size, Share & Trends Analysis Report by Type (Bioengineered Vaccine, Gene Therapy, Cell Therapy, Monoclonal Anti Body-Based Treatment, and Others) and by Application ( Infectious Diseases and Cancer) Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/mrna-vaccine-market

Furthermore, in May 2021, Defence Research and Development Organization (DRDO) has developed the 2-deoxy-D-glucose (2-DG). According to the Indian Council of Medical Research (ICMR), the drug has proved to be effective in the three phases of trials on COVID-19 patients. The Institute of Nuclear Medicine and Allied Sciences, a DRDO lab worked in partnership with Dr.Reddys Laboratories to develop the drug. This drug assists to reduce hospitalization time and oxygen dependency for moderate to severe cases. Thus, key acquisitions, developments, and collaborations are anticipated to propel the growth of the global mRNA vaccines market during the forecast period.

Market Coverage

  • The market number available for – 2021-2028
  • Base year- 2021
  • Forecast period- 2022-2028

Segment Covered- 

  • By Type 
  • By Application 

Regions Covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- are Arcturus Therapeutics Inc, BioNTech SE, CureVac AG, GlaxoSmithKline.Plc, Ethris GmbH, and others

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global mRNA Vaccine Market Report Segment

By Type 

  • Bioengineered vaccine 
  • Gene therapy
  • Cell therapy
  • Monoclonal Anti –Body-Based Treatment 

By Application

  • Cancer
  • Infectious Diseases

Global mRNA Vaccine Market Report Segment by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World

  • Latin America 
  • Middle East & Africa